ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,890Medicare Part D Prescriptions Filled, Including Refills

Rank: 201 out of 551

$261K Total Retail Price of All Prescriptions

Rank: 248 out of 551

478 Patients Receiving at Least One Drug in Part D
75%Patients 65 Years and Older
1% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Puerto Rico
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 478 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

4% of this provider’s 6,862 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$29 was the average price of a prescription from this provider, compared to $35 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 24.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Puerto Rico
SIMVASTATIN 492 356 1 1
GABAPENTIN 362 259 2 3
LOSARTAN POTASSIUM 305 255 3 6
METFORMIN HCL 272 189 4 2
TRAMADOL HCL-ACETAMINOPHEN 203 155 5 18
HUMULIN 70-30 196 158 6 35
DOXAZOSIN MESYLATE 184 145 7 25
OMEPRAZOLE 175 110 8 7
FUROSEMIDE 165 154 9 13
WARFARIN SODIUM 161 122 10 46
GLIPIZIDE 158 129 11 20
LEVOTHYROXINE SODIUM 156 103 12 9
RANITIDINE HCL 154 98 13 8
AMLODIPINE BESYLATE 150 125 14 4
ENALAPRIL MALEATE 145 132 15 5
ISOSORBIDE MONONITRATE ER 141 132 16 21
SYNTHROID 138 114 17 11
CARVEDILOL 134 103 18 22
ATORVASTATIN CALCIUM 129 119 19 29
LISINOPRIL 126 97 20 14
CILOSTAZOL 125 108 21 64
FAMOTIDINE 116 100 22 31
GLIMEPIRIDE 113 90 23 16
METOPROLOL SUCCINATE 108 83 24 23
PENTOXIFYLLINE 103 90 25 73
DICLOFENAC POTASSIUM 98 65 26 45
MEGESTROL ACETATE 93 90 R 27 115
AMITRIPTYLINE HCL 92 65 R 28 96
LOSARTAN-HYDROCHLOROTHIAZIDE 90 54 29 10
ATENOLOL 88 55 30 12
METOPROLOL TARTRATE 80 67 31 17
MECLIZINE HCL 74 57 32 56
LANTUS 68 52 33 28
CLOPIDOGREL 67 60 34 30
DONEPEZIL HCL 62 57 35 50
TORSEMIDE 59 57 36 346
DIGOXIN 59 47 36 44
CLOTRIMAZOLE-BETAMETHASONE 59 45 36 49
ZOLPIDEM TARTRATE 58 46 39 27
SPIRONOLACTONE 58 56 39 79
INSULIN SYRINGE 58 47 39 41
DIOVAN HCT 57 53 42 71
ORPHENADRINE CITRATE 53 30 R 43 147
HYDROCHLOROTHIAZIDE 53 50 43 15
ASPIRIN EC 53 53 43 26
LISINOPRIL-HYDROCHLOROTHIAZIDE 52 26 46 59
PLAVIX 50 50 47 33
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 9, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.